The Development GMP Gap: Why CDMO Performance Drops Exactly When It Matters Most

Many development programs lose momentum at the exact point they should accelerate — when transitioning from formulation to GMP manufacturing. This challenge is not rooted in science, but in how organizations manage the shift from flexible, insight-driven development to structured, execution-focused production. As cross-functional handoffs increase, communication gaps, misaligned priorities, and incomplete knowledge transfer often create friction that slows progress and introduces risk.

A more effective approach aligns development and GMP as a continuous, integrated process. Cross-functional teams share ownership of outcomes, knowledge evolves alongside the program, and decisions are made with full visibility into downstream implications. By building workflows that generate the data needed for clinical manufacturing from the start, organizations can reduce inefficiencies and stay on track when it matters most.

Learn how rethinking organizational structure and execution models can close the development–GMP gap and improve performance across the drug development lifecycle.